AXL and bile duct cancer: The present study showed that AVB-500 treatment reduces tumor growth and invasion in AXL-expressing bile duct cancer cells (SNU1196, HUCCT1) compared to non-AXL expressing tumor cells (SNU478 and SNU869), suggesting that AXL expression and activation can be used as diagnostic factors to identify patient groups who will most likely benefit from AXL-targeted therapy.